TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years but \<60 years; body mass index ≥18 but \<30 kg/m2;~2. Scheduled to undergo elective bimaxillary surgery under general anesthesia;~3. Planned to use patient-controlled intravenous analgesia (PCIA) after surgery;~4. Provide written informed consents.~Exclusion Criteria:~1. Presence of glaucoma;~2. Allergic to penehyclidine, atropine, scopolamine or other anticholinergic drugs;~3. Acute or chronic nausea and/or vomiting, or gastrointestinal motility disorders before surgery;~4. Preoperative antiemetic therapy within 12 hours;~5. History of schizophrenia, Parkinson's disease or profound dementia, or language barrier;~6. Severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (requirement of renal replacement therapy before surgery) or American Society of Anesthesiologists physical status ≥IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): For patients in the control group, a dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron 10 mg, diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
- Single injection group (Type: EXPERIMENTAL): For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
- Continuous infusion group (Type: EXPERIMENTAL): For patients in this group, a dose of penehyclidine (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female 9 years of age or older~2. Females must not be pregnant or planning to get pregnant and must use acceptable form of contraception~3. Must be able to self-administer study medication~4. Must be able to understand and sign an informed consent form. For minor subjects, the subject's parent or legal guardian must provide permission by signing an ICF on behalf of the subject and the subject should provide assent.~Exclusion Criteria:~1. Congenital ptosis~2. Horner syndrome~3. Myasthenia gravis~4. Mechanical ptosis~5. Previous ptosis surgery~6. Resting heart rate outside the normal range~7. Hypertension with resting diastolic blood pressure~8. Pregnancy or lactation

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RVL-1201 ophthalmic solution 0.1% (Type: EXPERIMENTAL): RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
- Vehicle ophthalmic solution (Type: PLACEBO_COMPARATOR): Vehicle placebo ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has given written informed consent before any trial-related activity is performed.~* Has a confirmed prostate cancer in which this type of treatment is needed.~Exclusion Criteria:~* Previous treatment for prostate cancer~* Previous trans-urethral resection of the prostate~* Patients who are lymph node positive or have other metastatic disease~* Use of urethral catheter~* Current treatment with a 5-alpha reductase inhibitor or α-adrenoceptor antagonist.~* History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.~* Hypersensitivity towards any component of the investigational product~* Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.~* Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)~* Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/80 mg (Type: EXPERIMENTAL): The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
- Goserelin (3.6 mg) + bicalutamide (50 mg) (Type: ACTIVE_COMPARATOR): On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Bevacizumab for Preventing Recurrent Pterygium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are diagnosed with primary pterygium and plan for pterygium excision with bare sclera by single surgeon. (G.N.)~* Patients with pterygium who understand and can follow the study protocol.~* Patients of age more than 30 years~Exclusion Criteria:~* Patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial wound healing.~* Patients who are pregnancy or lactation.~* Patients who have a history of allergy to bevacizumab.~* Patients who have a history of allergy to steroid eye drops

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- bevacizumab eye drop (Type: EXPERIMENTAL): None
- placebo normal saline eye drop (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The inclusion criteria were ulcer healing confirmed by follow-up endoscopy, a negative test for Helicobacter pylori or successful eradication of Helicobacter pylori based on histology, and anticipated regular use of NSAIDs for the duration of the trial. The exclusion criteria were concomitant use of low-dose aspirin, anticoagulants or corticosteroids; a history of gastric or duodenal surgery other than a patch repair; the presence of erosive esophagitis, gastric outlet obstruction, renal failure (defined by a serum creatinine level of more than 2.26 mg per deciliter), terminal illness, or cancer.~Exclusion Criteria:~* The exclusion criteria were concomitant use of low-dose aspirin, anticoagulants or corticosteroids; a history of gastric or duodenal surgery other than a patch repair; the presence of erosive esophagitis, gastric outlet obstruction, renal failure (defined by a serum creatinine level of more than 2.26 mg per deciliter), terminal illness, or cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current CHA patient with an enrolled CHA primary care doctor.~* CHA patients 18 years of age and older.~* Able to tolerate and participate in interviews and engage in all procedures.~* Able to give written consent in English OR willing and able to provide consent and complete assessments through a professional language translator when necessary.~* Diagnosis eligible to be covered by insurance for group visits (e.g., anxiety disorder, depression, or adjustment disorder related to chronic illness, pain, etc.).~Exclusion Criteria:~* Any cognitive impairment that precludes informed consent.~* Patients who, in the opinion of the Principal Investigator, pose an imminent risk of suicide or danger to self or others.~* Likelihood of potential incarceration such as a conviction or pending charges that may potentially result in imprisonment.~* Previous enrollment or randomization of treatment in the present study within the 12 months.~* Behaviors that may cause disruption to a mindfulness group.~* Patients with symptoms of psychosis, thought disorder, and/or severe mental illness, including schizophrenia, schizoaffective, bipolar disorder, or a current severe episode of major depressive disorder.~* Lack of insurance coverage for group psychotherapy may preclude participation in groups.~* Patients in their third trimester of pregnancy who foresee conflicts that preclude their commitment to completing all activities.~* Patients with highly unstable medical problems that put them at a high risk of hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mindfulness Training for Primary Care (Type: ACTIVE_COMPARATOR): Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
- Low-dose Comparator (Type: OTHER): Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically proven, previously untreated extensive stage small cell lung cancer (SCLC) Brain metastases allowed if: Asymptomatic OR Previously treated with radiotherapy and/or surgery Measurable or evaluable disease outside the area of prior surgical resection or a new lesion must be present~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) SGOT or SGPT no greater than 2.5 times ULN Renal: Creatinine no greater than ULN Creatinine clearance at least 50 mL/min Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any stage I or II cancer that is in complete remission~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior systemic biologic therapy for SCLC Chemotherapy: No prior systemic chemotherapy for SCLC Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior radiotherapy for SCLC Surgery: See Disease Characteristics At least 2 weeks since prior thoracic or other major surgery and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between the ages of 18 years and 60 years will be selected for the study if they have a clinical diagnosis of Raynaud's phenomenon secondary to systemic sclerosis (scleroderma). Raynaud's phenomenon is defined as a history of cold sensitivity associated with colour changes of cyanosis or pallor, as well as a history of at least 4 attacks per week during two pre-trial period even with treatment with other vasodilators. The diagnosis of scleroderma is defined by the American College of Rheumatology (ACR) criteria or by the presence of at least 3 of the 5 features of the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias).~Exclusion Criteria:~Patients will be excluded if they have:~* Symptomatic orthostatic hypotension~* Evidence of current malignancy~* History of sympathectomy~* Upper extremity deep vein thrombosis or lymphedema within 3 months~* Recent surgical procedure requiring general anesthesia~* AMI, unstable angina, strokes and TIA within the past three months~* Smoking~* Use of any investigational drug within 30 days of the study sessions~* Use of medications that might interfere with tadalafil like nitrates and alpha adrenergic blockers that have vasoactive effects, and patients taking potent inhibitors of CYP3A4 such as ritonavir, ketoconazole, and itraconazole, erythromycin, itraconazole, and grapefruit juice~* Patients taking alcohol~* Patients with bleeding disorders~* Significant active peptic ulceration~* Current pregnancy~* Current breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): One placebo tablet every alternate day for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes~* Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment~* HbA1c \>6.5% and \</=10%~Exclusion Criteria:~* Type 1 Diabetes~* Insulin therapy within one year of enrolment~* Renal (kidney) failure or dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dapagliflozin plus metformin
- 2 (Type: ACTIVE_COMPARATOR): glipizide plus metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants between 24 and 33 6/7 weeks gestation~* must be less than or equal to 1 week of age~Exclusion Criteria:~* infants who are considered by the medical team to be non-viable~* infants with multiple or severe congenital anomalies such as gastroschisis, congenital chylothorax or other illnesses that do not allow a feeding tube to be placed or utilized at 7 days of age.~* term infants: who are born to mothers with diabetes or are small for gestational age (SGA-less than the 10th% for adjusted gestational age~* All families consented for this study will need to be able to read and write English~* Mother must be 18 years of age or older~* Taking Omegaven

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 33 Weeks
- Healthy Volunteers: t

Study Arms:
- DHA oil (Type: ACTIVE_COMPARATOR): DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
- (MCT) control oil (Type: PLACEBO_COMPARATOR): MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* are at least 18 and less than 65 years;~* sign written informed consent after the scope and nature of the investigation have been explained;~* have shown capability to complete the LogPad questionnaires;~* have difficulty falling asleep, maintaining sleep or have early morning awakening;~Exclusion Criteria:~* Significant medical or psychiatric illness causing sleep disturbances.~* Have a history of bipolar disorder or attempted suicide or have a family (immediate family) history of suicide.~* Have a sleep disorder such as sleep-related breathing disorder, restless leg syndrome, narcolepsy.~* Significant other medical illness such as acute or chronic pain, heart-, kidney-, or liver disease within the last year.~* Currently diagnosed or meet the criteria for Major Depressive Disorder (MDD) or have been treated for MDD in the last 2 years.~* Substance abuse, excessive use of alcohol (determined by the physician) or drug addiction within the last year.~* Are night workers or rotating shift workers or plan to travel through more than 3 time-zones.~* Routinely nap during the day.~* Have a Body Mass Index (BMI) of 36 or more.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Esmirtazapine 4.5 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo tablets, administered once a day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Males and females between 18 and 60 years of age.~2. History of grass and/or ragweed allergic rhinitis.~3. Positive skin or RAST test to grass, trees and/or ragweed antigen.~4. Symptomatic at time of entry into study.~Exclusion Criteria~1. Women of childbearing potential not using the contraception method(s) (Birth control pills, depo Provera, double barrier) as well as women who are pregnant or breastfeeding.~2. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease).~3. Use of any other investigational agent in the last 30 days.~4. Absence of nasal symptoms.~5. Smoking.~6. URI at the time of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 2 weeks of treatment
- 2 (Type: PLACEBO_COMPARATOR): 2 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete